uniQure (NASDAQ:QURE) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of uniQure (NASDAQ:QURE) from a hold rating to a sell rating in a report released on Sunday.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group lowered their target price on uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. UBS Group set a $95.00 price objective on shares of uniQure in a research note on Thursday, September 25th. Guggenheim lifted their price objective on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 25th. William Blair reiterated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Finally, Stifel Nicolaus decreased their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $60.82.

uniQure Stock Up 9.4%

Shares of NASDAQ QURE opened at $25.32 on Friday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The business’s 50 day moving average is $25.46 and its two-hundred day moving average is $27.61. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -5.77 and a beta of 0.68.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. Research analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the sale, the director directly owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the business’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. The trade was a 65.50% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.79% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. Avoro Capital Advisors LLC boosted its position in shares of uniQure by 22.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after acquiring an additional 819,444 shares in the last quarter. Aberdeen Group plc raised its position in shares of uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in uniQure during the second quarter worth approximately $29,217,000. Franklin Resources Inc. boosted its holdings in uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after purchasing an additional 383,066 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA Type A meeting scheduled to discuss AMT‑130 BLA — this advances the company’s pathway to accelerated approval and reduces near‑term regulatory uncertainty around whether the FDA will accept the submitted data package. uniQure Announces Type A Meeting Scheduled with FDA
• Positive Sentiment: Multiple market outlets report shares jumped on the news, reflecting investor optimism that a formal FDA meeting could clarify approval requirements and timing for AMT‑130. UniQure Climbs on Scheduling FDA Meeting for Huntington’s Disease Treatment
• Neutral Sentiment: Company and analyst outlets are preparing commentary and analyses as the Type A meeting approaches; these pieces summarize the regulatory next steps but don’t yet change the underlying clinical or financial data. uniQure prepares for FDA Type A meeting on AMT-130
• Negative Sentiment: Regulatory uncertainty remains: recent reporting highlights a prior FDA shift on using external controls for AMT‑130 that delayed submission plans, signaling the meeting could still result in significant requests or delays. uniQure: Now What?
• Negative Sentiment: A securities investigation has been announced regarding uniQure, which can increase legal risk and create headline volatility independent of clinical progress. QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.